Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Candel Therapeutics, Inc. (CADL : NSDQ)

• Company Description    Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass. Number of Employees: 55

• Price / Volume Information    Yesterday's Closing Price: $7.99 Daily Weekly Monthly 20 Day Moving Average: 2,220,753 shares Shares Outstanding: 73.27 (millions) Market Capitalization: $585.43 (millions) Beta: -0.59 52 Week High: $9.27 52 Week Low: $4.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.49% 7.95% 12 Week 55.15% 43.42% Year To Date 41.42% 29.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 117 KENDRICK STREET SUITE 450 - NEEDHAM,MA 02494 USA ph: 617-916-5445 fax: - tjenkins@candeltx.com http://www.candeltx.com

• General Corporate Information    Officers Paul Peter Tak - President and Chief Executive Officer Paul B. Manning - Chairman Charles Schoch - Chief Financial Officer Edward J. Benz - Director Chris Martell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 137404109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 73.27 Most Recent Split Date: (:1) Beta: -0.59 Market Capitalization: $585.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.97 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 10.28% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.24 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -207.69% vs. Previous Quarter: 74.07% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -60.42 12/31/25 - -51.44 09/30/25 - -29.24 ROA 03/31/26 - -41.33 12/31/25 - -36.31 09/30/25 - -22.63 Current Ratio 03/31/26 - 28.05 12/31/25 - 13.49 09/30/25 - 8.25 Quick Ratio 03/31/26 - 28.05 12/31/25 - 13.49 09/30/25 - 8.25 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 1.88 12/31/25 - 0.95 09/30/25 - 1.46 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.34 12/31/25 - 0.91 09/30/25 - 0.01 Debt-to-Capital 03/31/26 - 25.59 12/31/25 - 47.58 09/30/25 - 1.20

Powered by Zacks Investment Research ©